India's Cipla signs pact with Lilly to sell weight loss drug tirzepatide in India
23/10/2025 11:08
Oct 23 (Reuters) - Indian drugmaker Cipla CIPL.NS signed an agreement with Eli Lilly LLY.N to sell tirzepatide, the active ingredient in the U.S. company's blockbuster weight-loss drug Mounjaro, in India, the companies said on Thursday. (Reporting by Kashish Tandon in Bengaluru) ((Kashish.Tandon@thomsonreuters.com; 8800437922;))
Recent news on Cipla
See all newsIndian pharma stocks up on report US taps drugmakers for critical cancer drug
India's Cipla jumps after Citi sees near-term positive triggers for earnings
Factbox: Global drugmakers invest billions to boost US presence
India raises price cap on cancer drugs to tackle shortage
Brief: Cipla Says USFDA Classified Verna Manufacturing Facility Inspection As Voluntary Action Indicated